These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 35230650)

  • 1. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Tolerability of Once-Weekly GLP-1 Receptor Agonists in Clinical Practice: A Focus on Switching Between Once-Weekly Molecules in Type 2 Diabetes.
    Di Dalmazi G; Coluzzi S; Baldassarre MPA; Ghit A; Graziano G; Rossi MC; Ciappini B; Milo M; Carrieri F; Nicolucci A; Consoli A; Formoso G
    Front Endocrinol (Lausanne); 2022; 13():892702. PubMed ID: 35909534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: Real-world data from a diabetes out-patient clinic.
    Hansen KB; Svendstrup M; Lund A; Knop FK; Vilsbøll T; Vestergaard H
    Diabet Med; 2021 Oct; 38(10):e14655. PubMed ID: 34291491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.
    Yale JF; Bodholdt U; Catarig AM; Catrina S; Clark A; Ekberg NR; Erhan U; Holmes P; Knudsen ST; Liutkus J; Sathyapalan T; Schultes B; Rudofsky G
    BMJ Open Diabetes Res Care; 2022 Apr; 10(2):. PubMed ID: 35383100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: Results from a nationwide observational study in people with type 2 diabetes.
    Vilsbøll T; Lindahl CØ; Nielsen NF; Tikkanen CK
    Diabetes Obes Metab; 2023 Jun; 25(6):1740-1749. PubMed ID: 36809678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain.
    Garcia de Lucas MD; Miramontes-González JP; Avilés-Bueno B; Jiménez-Millán AI; Rivas-Ruiz F; Pérez-Belmonte LM
    Front Endocrinol (Lausanne); 2022; 13():995646. PubMed ID: 36187123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Once-Weekly Semaglutide on Cardiovascular Risk Factors and Metabolic Dysfunction-Associated Steatotic Liver Disease in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study Based on Real-World Data.
    Katsuyama H; Hakoshima M; Kaji E; Mino M; Kakazu E; Iida S; Adachi H; Kanto T; Yanai H
    Biomedicines; 2024 May; 12(5):. PubMed ID: 38790963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study.
    Wolffenbuttel BHR; Brugts MP; Catarig AM; Clark A; Kok M; Lieverse AG; van Soest J
    Adv Ther; 2023 Mar; 40(3):920-933. PubMed ID: 36542260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly semaglutide use in glucagon-like peptide-1 receptor agonist naïve patients with type 2 diabetes in North Macedonia: Real-world data from the MIRAGE study.
    Milenkovikj T; Chekorova Mitreva B; Jovanovska Mishevska S; Bitoska-Mileva I; Ahmeti I;
    Diabetes Res Clin Pract; 2023 Dec; 206():111018. PubMed ID: 37972857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
    Williams DM; Ruslan AM; Khan R; Vijayasingam D; Iqbal F; Shaikh A; Lim J; Chudleigh R; Peter R; Udiawar M; Bain SC; Stephens JW; Min T
    Diabetes Ther; 2021 Mar; 12(3):801-811. PubMed ID: 33565043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: Results from the SURE Canada multicentre, prospective, observational study.
    Yale JF; Catarig AM; Grau K; Harris S; Klimek-Abercrombie A; Rabasa-Lhoret R; Reardon L; Woo V; Liutkus J
    Diabetes Obes Metab; 2021 Oct; 23(10):2269-2278. PubMed ID: 34142429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes in Treatment Intensification: A Retrospective Observational Single-Center Study.
    Yamada H; Yoshida M; Suzuki D; Funazaki S; Nagashima S; Masahiko K; Kiyoshi O; Hara K
    Diabetes Ther; 2022 Oct; 13(10):1779-1788. PubMed ID: 36006593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Jun; 13(6):1251. PubMed ID: 35461397
    [No Abstract]   [Full Text] [Related]  

  • 20. Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).
    Brown RE; Bech PG; Aronson R
    Diabetes Obes Metab; 2020 Nov; 22(11):2013-2020. PubMed ID: 32538541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.